AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3553759 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid, shallow breathing with methacholine
Number of subjects: 12
Study 3553759 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow, deep breathing with methacholine
Number of subjects: 12
Study 31953058 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhexis-fixated IOL
Number of subjects: 56
Study 31953058 — intervention group
Group type: COMPARATOR
Intervention: C-loop haptic IOL
Number of subjects: 56
Study 31953058 — intervention group
Group type: COMPARATOR
Intervention: Plate-haptic IOL
Number of subjects: 56
Study 28806104 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (Left DLPFC, 10 Hz, 110% rMT, 4000 pulses)
Number of subjects: 18
Study 28806104 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study 27009938 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Debulking Surgery (PDS)
Number of subjects: 0
Study 27009938 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy followed by Interval Debulking Surgery (NACT-IDS)
Number of subjects: 0
Study 25760680 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK solution (insulin 0.1 IU kg(‐1) h(‐1) and an infusion of 30% dextrose and 80 mmol l(‐1) potassium at 0.5 ml kg(‐1) h(‐1))
Number of subjects: 106
Study 25760680 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 106
Study 25760680 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK solution
Number of subjects: 106
Study 23780952 — intervention group
Group type: EXPERIMENTAL
Intervention: MLC601
Number of subjects: 1100
Study 23780952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1100
Study 21195294 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 79
Study 21195294 — intervention group
Group type: COMPARATOR
Intervention: Non-penetrating sham acupuncture
Number of subjects: 79
Study 19553398 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of atrial fibrillation (AF) in CHF patients
Number of subjects: 53969
Study 17892983 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic guidance with fractional flow reserve (FFR)
Number of subjects: 0
Study 17892983 — intervention group
Group type: COMPARATOR
Intervention: Angiographic guidance
Number of subjects: 0
Study 15079782 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoComb H patches
Number of subjects: 24
Study 15079782 — intervention group
Group type: COMPARATOR
Intervention: Standard compression with surgical swabs (Control)
Number of subjects: 24
Study 11233879 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic therapy
Number of subjects: 23
Study 11233879 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study 9031957 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.25% with adrenaline 1:200 000 (n = 500)
Number of subjects: 1000
Study 9031957 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with 10 micrograms sufentanil (n = 500)
Number of subjects: 1000
Study 9031957 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EDA)
Number of subjects: 1000
Study 7838644 — intervention group
Group type: EXPERIMENTAL
Intervention: LAT gel (4% lidocaine, 1:2000 adrenaline, 0.5% tetracaine)
Number of subjects: 95
Study 7838644 — intervention group
Group type: COMPARATOR
Intervention: TAC gel (0.5% tetracaine, 1:2000 adrenaline, 11.8% cocaine)
Number of subjects: 95
Study 7838644 — intervention group
Group type: EXPERIMENTAL
Intervention: LAT gel
Number of subjects: 95
Study 7838644 — intervention group
Group type: COMPARATOR
Intervention: TAC gel
Number of subjects: 95
Study 7838644 — intervention group
Group type: EXPERIMENTAL
Intervention: LAT gel and TAC gel
Number of subjects: 95
Study 2197909 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aid (n = 95)
Number of subjects: 194
Study 2197909 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (n = 99)
Number of subjects: 194
Study 699788 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (3 x 40 mg/d or 3 x 80 mg/d)
Number of subjects: 61
Study 699788 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (with spironolactone 50 mg/d, thiabutazide 5 mg/d, and dihydralazine 3 x 25 mg/d)
Number of subjects: 61
Study 699788 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (3 x 40 mg/d)
Number of subjects: 61
Study 699788 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic beta-adrenergic blockade
Number of subjects: 61
Study 699788 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol treatment
Number of subjects: 61
Study 30633058 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative music intervention
Number of subjects: 195
Study 30633058 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and intraoperative music intervention
Number of subjects: 195
Study 30633058 — intervention group
Group type: COMPARATOR
Intervention: Control (no music intervention)
Number of subjects: 195
Study 31223480 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 66
Study 31223480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 28494509 — intervention group
Group type: EXPERIMENTAL
Intervention: 19 mg ferrous gluconate
Number of subjects: 0
Study 28494509 — intervention group
Group type: EXPERIMENTAL
Intervention: 38 mg ferrous gluconate
Number of subjects: 0
Study 28494509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28494509 — intervention group
Group type: COMPARATOR
Intervention: No pill
Number of subjects: 0
Study 25947181 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary self-management intervention (8-week health education, exercise sessions, individual empowerment counseling, followed by 16-week self-help group activities)
Number of subjects: 43
Study 25947181 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-disciplinary self-management intervention
Number of subjects: 43
Study 25947181 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 43
Study 26552322 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical antipsychotic dose reduction
Number of subjects: 0
Study 26552322 — intervention group
Group type: COMPARATOR
Intervention: Once-daily perphenazine dosing
Number of subjects: 0
Study 26552322 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily perphenazine dosing
Number of subjects: 0
Study 23168366 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy (2.5 mg/kg per week equivalent, either 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks, intravenously)
Number of subjects: 820
Study 23168366 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 820
Study 19443169 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-completion concordance forms
Number of subjects: 0
Study 19443169 — intervention group
Group type: COMPARATOR
Intervention: Usual information and instruction on how to use the medicine (Control)
Number of subjects: 0
Study 18379357 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg
Number of subjects: 53
Study 18379357 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 200 mg
Number of subjects: 53
Study 18379357 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg
Number of subjects: 53
Study 16530990 — intervention group
Group type: EXPERIMENTAL
Intervention: Early post‐discharge developmental mother‐child intervention program
Number of subjects: 36
Study 16530990 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 14673218 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone CR (150 mg)
Number of subjects: 549
Study 10807482 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Unilateral ECT (RUL ECT) at high dosage (150% or 500% above seizure threshold)
Number of subjects: 80
Study 10807482 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT (BL ECT) at high dosage (150% above seizure threshold)
Number of subjects: 80
Study 10807482 — intervention group
Group type: COMPARATOR
Intervention: Low-dosage Unilateral ECT
Number of subjects: 80
Study 10807482 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dosage Unilateral ECT
Number of subjects: 80
Study 10807482 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT (BL ECT)
Number of subjects: 80
Study 10807482 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT (all groups)
Number of subjects: 80
Study 9144763 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling and self-help materials
Number of subjects: 0
Study 9144763 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 7695258 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg genaconazole tablets orally
Number of subjects: 12
Study 7695258 — intervention group
Group type: COMPARATOR
Intervention: 100 mg genaconazole intravenous infusion
Number of subjects: 12
Study 3234625 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic salmon calcitonin (415 pmol bolus injection followed by infusion to reach an overall dose of 62.25 pmol.kg‐1 body mass)
Number of subjects: 13
Study 3234625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 29290000 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin tromethamine (3 g, two oral doses)
Number of subjects: 216
Study 29290000 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care antibiotic therapy (control group)
Number of subjects: 216
Study 29290000 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin tromethamine
Number of subjects: 216
Study 26610176 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based care (H)
Number of subjects: 426
Study 26610176 — intervention group
Group type: COMPARATOR
Intervention: Facility-based care (F)
Number of subjects: 426
Study 25384116 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender-thymol
Number of subjects: 60
Study 25384116 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23702435 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual ketorolac (0.5 mg/kg)
Number of subjects: 131
Study 23702435 — intervention group
Group type: COMPARATOR
Intervention: Sublingual tramadol (2 mg/kg)
Number of subjects: 131
Study 20464263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular vaccination
Number of subjects: 149
Study 20464263 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccination
Number of subjects: 149
Study 18379366 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0
Study 18379366 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 0
Study 18379366 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study 18379366 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 0
Study 18379366 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study 16801333 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic communication skills training programme (BT)
Number of subjects: 0
Study 16801333 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic communication skills training programme (BT) with consolidation workshops (CW)
Number of subjects: 0
Study 14685040 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization therapy with Cry j 1 at doses of 0.01 microg/ml, 0.1 microg/ml, 1 microg/ml, and 10 microg/ml.
Number of subjects: 22
Study 14685040 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-IgE therapy.
Number of subjects: 22
Study 14685040 — intervention group
Group type: COMPARATOR
Intervention: Hyposensitization therapy (duration not specified).
Number of subjects: 22
Study 14685040 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization therapy.
Number of subjects: 22
Study 10957832 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweetener
Number of subjects: 25
Study 8996937 — intervention group
Group type: EXPERIMENTAL
Intervention: ETS exposure (Group II)
Number of subjects: 172
Study 8996937 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomass exposure (Group III)
Number of subjects: 172
Study 8996937 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group I)
Number of subjects: 172
Study 8996937 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ETS and biomass exposure
Number of subjects: 172
Study 8996937 — intervention group
Group type: EXPERIMENTAL
Intervention: ETS exposure with exposure index (EI) of 50 or more
Number of subjects: 172
Study 7942121 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiometric ingestion assay (IN)
Number of subjects: 0
Study 7942121 — intervention group
Group type: COMPARATOR
Intervention: Luminol-enhanced chemiluminescence (LCL) in response to phorbol esters
Number of subjects: 0
Study 7942121 — intervention group
Group type: COMPARATOR
Intervention: Luminol-enhanced chemiluminescence (LCL) during phagocytosis of opsonized Staphylococcus aureus (STLCL)
Number of subjects: 0
Study 7942121 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro data at glucose concentrations > or = 13.8 mmol/L
Number of subjects: 0
Study 7942121 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro data at glucose levels > or = 27.75 mmol/L
Number of subjects: 0
Study 7942121 — intervention group
Group type: COMPARATOR
Intervention: Correlation of peak LCL response and IN in control group
Number of subjects: 0
Study 7942121 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of peak LCL response and IN in diabetic patients
Number of subjects: 0
Study 3496186 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated fenoprofen calcium (600 mg q.i.d.)
Number of subjects: 32
Study 3496186 — intervention group
Group type: COMPARATOR
Intervention: Plain fenoprofen calcium (600 mg q.i.d.)
Number of subjects: 32
Study 3496186 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (enteric-coated and plain)
Number of subjects: 32
Study 31375042 — intervention group
Group type: EXPERIMENTAL
Intervention: rtCGM (Dexcom G5)
Number of subjects: 40
Study 31375042 — intervention group
Group type: COMPARATOR
Intervention: iscCGM (Freestyle Libre)
Number of subjects: 40
Study 31375042 — intervention group
Group type: COMPARATOR
Intervention: iscCGM switching to rtCGM
Number of subjects: 40
Study 29354932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (heat sensitive moxibustion + acupoint injection)
Number of subjects: 210
Study 29354932 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat sensitive moxibustion
Number of subjects: 210
Study 29354932 — intervention group
Group type: COMPARATOR
Intervention: Control (intravenous drip of cefoxitin sodium)
Number of subjects: 210
Study 27394380 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light therapy using a Litebook treatment device for 30 minutes daily for 4 weeks
Number of subjects: 0
Study 27394380 — intervention group
Group type: COMPARATOR
Intervention: Dim red light therapy using a Litebook treatment device for 30 minutes daily for 4 weeks
Number of subjects: 0
Study 27394380 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light therapy
Number of subjects: 0
Study 27394380 — intervention group
Group type: COMPARATOR
Intervention: Dim red light therapy
Number of subjects: 0
Study 24824768 — intervention group
Group type: EXPERIMENTAL
Intervention: R-maintenance (rituximab maintenance) every 2 months for 2 years
Number of subjects: 545
Study 24824768 — intervention group
Group type: EXPERIMENTAL
Intervention: R-maintenance (rituximab maintenance)
Number of subjects: 545
Study 22417252 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure with a percutaneous device
Number of subjects: 909
Study 22417252 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 909
Study 20461068 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (peginterferon alpha-2a 180 microg weekly plus placebo)
Number of subjects: 138
Study 20461068 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (peginterferon alpha-2a weekly plus ribavirin 1,000 or 1,200 mg daily)
Number of subjects: 138
Study 20461068 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 138
Study 20461068 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 138
Study 20461068 — intervention group
Group type: EXPERIMENTAL
Intervention: Both therapies
Number of subjects: 138
Study 18852544 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU cholecalciferol per day
Number of subjects: 216
Study 18852544 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 IU cholecalciferol per day
Number of subjects: 216
Study 18852544 — intervention group
Group type: COMPARATOR
Intervention: 0 IU cholecalciferol per day (placebo)
Number of subjects: 216
Study 16900385 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard infusion therapy with acute medical intervention
Number of subjects: 93
Study 16900385 — intervention group
Group type: COMPARATOR
Intervention: Standard infusion therapy with acute medical intervention plus psychotherapeutic intervention
Number of subjects: 93
Study 14657697 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of cyclosporine A (CsA)
Number of subjects: 24
Study 14657697 — intervention group
Group type: COMPARATOR
Intervention: Continuation of cyclosporine A (CsA)
Number of subjects: 24
Study 10811675 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m²
Number of subjects: 104
Study 10811675 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m²
Number of subjects: 104
Study 10811675 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 104
Study 8772621 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (up to 2000 mg day‐1)
Number of subjects: 60
Study 8772621 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (in normal weight subgroup)
Number of subjects: 60
Study 8772621 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (in overweight subgroup)
Number of subjects: 60
Study 8772621 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 60
Study 20169701 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle biopsy (Tru-cut R) of the testis
Number of subjects: 45
Study 20169701 — intervention group
Group type: COMPARATOR
Intervention: Open testicular biopsy
Number of subjects: 45
Study 6133791 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (Naprosyn)
Number of subjects: 21
Study 6133791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31481553 — intervention group
Group type: EXPERIMENTAL
Intervention: ICAN Discussion Aid
Number of subjects: 100
Study 31481553 — intervention group
Group type: COMPARATOR
Intervention: Control encounters
Number of subjects: 100
Study 31481553 — intervention group
Group type: EXPERIMENTAL
Intervention: ICAN encounters
Number of subjects: 100
Study 30153782 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal fluid resuscitation (≥ 3250 mL of fluid administered)
Number of subjects: 144
Study 30153782 — intervention group
Group type: EXPERIMENTAL
Intervention: High fluid group (≥ 3250 mL of fluid administered)
Number of subjects: 144
Study 30153782 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal fluid group and high fluid group in patients with EuroSCORE II ≥ 0.9
Number of subjects: 144
Study 30153782 — intervention group
Group type: COMPARATOR
Intervention: Conservative fluid resuscitation
Number of subjects: 144
Study 26352680 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity defined by Body Mass Index (BMI)
Number of subjects: 2300
Study 26352680 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity defined by Waist-to-Hip Ratio (WHR)
Number of subjects: 2300
Study 26352680 — intervention group
Group type: COMPARATOR
Intervention: Normal WHR and BMI
Number of subjects: 2300
Study 26352680 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 2300
Study 26352680 — intervention group
Group type: EXPERIMENTAL
Intervention: WHR
Number of subjects: 2300
Study 24232052 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-jet assisted POEM (WJ group)
Number of subjects: 100
Study 24232052 — intervention group
Group type: COMPARATOR
Intervention: Conventional POEM technique (C group)
Number of subjects: 100
Study 21789587 — intervention group
Group type: COMPARATOR
Intervention: Standard palliative care consultation (control group)
Number of subjects: 80
Study 21789587 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high anxiety levels
Number of subjects: 80
Study 21789587 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with estimated survival of >12 weeks
Number of subjects: 80
Study 21225177 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-oriented incentive spirometer
Number of subjects: 17
Study 21225177 — intervention group
Group type: COMPARATOR
Intervention: Flow-oriented incentive spirometer
Number of subjects: 17
Study 21225177 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing
Number of subjects: 17
Study 17666464 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring in women with type 1 diabetes
Number of subjects: 57
Study 17666464 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring in women with type 2 diabetes
Number of subjects: 57
Study 15799079 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated emotion‐oriented care
Number of subjects: 146
Study 15799079 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 146
Study 12038872 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha (6 MU/m² body surface area for 6 months)
Number of subjects: 0
Study 12038872 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (3 mg/kg once daily in children up to 12 years of age)
Number of subjects: 0
Study 9459253 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 3 mL (2%)
Number of subjects: 175
Study 9459253 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 40 mg
Number of subjects: 175
Study 9459253 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 150 microg
Number of subjects: 175
Study 9459253 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 4 mg
Number of subjects: 175
Study 9459253 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 3 mL (placebo)
Number of subjects: 175